(Pyrimidin-1(2H)-yl)acetic acid | 4425-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Pyrimidin-1(2H)-yl)acetic acid
• 英文别名: 2-(2H-pyrimidin-1-yl)acetic acid
• CAS: 4425-48-3
• 化学式: C₆H₈N₂O₂
• 分子量: 140.14
• InChiKey: FHARGMSSJPHLMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] NOVEL PROCESSES<br/>[FR] NOUVEAUX PROCÉDÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2011146494A1

  公开（公告）日：2011-11-24

  This invention relates to methods of making a compound of formula (I) and intermediates for same. The compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.

  本发明涉及制备化合物（I）的方法以及用于制备该化合物的中间体。化合物（I）对治疗心血管和炎症性疾病如动脉粥样硬化具有益处。
• [EN] TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE TRIAZOLO[4,5-D] PYRIMIDINE ET LEUR UTILISATION EN TANT QU'AGONISTES DE RECEPTEUR PURINERGIQUE
  申请人：VERNALIS RES LTD

  公开号：WO2002055083A1

  公开（公告）日：2002-07-18

  The use of a compound of formula (I): wherein R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6,NR4CO2R7 and NR4SO2R7; R2 is selected from aryl attached via an unsaturated carbon; R3 is selected from H, alkyl, COR5, CO2 R7, CONR5R6, CONR4NR5R6 and SO2R7; R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4,R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and R7 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.

  使用式(I)的化合物，其中R1从H，烷基，芳基，烷氧基，芳氧基，烷硫基，芳硫基，卤素，CN，NR5R6，NR4COR5，NR4CONR5R6，NR4CO2R7和NR4SO2R7中选择；R2从通过不饱和碳连接的芳基中选择；R3从H，烷基，COR5，CO2R7，CONR5R6，CONR4NR5R6和SO2R7中选择；R4，R5和R6独立地从H，烷基和芳基中选择，或者当R5和R6在NR5R6基团中时，R5和R6可以连接形成杂环基团，或者当R4，R5和R6在(CONR4NR5R6)基团中时，R4和R5可以连接形成杂环基团；R7从烷基和芳基中选择，或其药学上可接受的盐或前药，在治疗或预防阻断嘌呤受体，特别是腺苷受体，更具体地是A2A受体可能有益的疾病中使用，特别是其中所述疾病是运动障碍，如帕金森病，或所述疾病是抑郁症，认知或记忆障碍，急性或慢性疼痛，ADHD或嗜睡症，或用于保护神经系统。式(I)的化合物用于治疗；以及式(I)的新化合物本身。
• Carboxyalkyl heterocyclic derivatives
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0718290A1

  公开（公告）日：1996-06-26

  A compound is provided represented by the following general formula (A) wherein two of Ra, Rb and Rc are oxygen; X is a kind of benzyl, a kind of benzothiazolylmethyl, or a kind of naphthylmethyl; R is hydrogen or lower alkyl; n is an integer of 1 to 3; and Z indicates a direct bond or a bridging moiety containing one carbon atom. The compounds act as selective inhibitors of aldose reductase. The compounds provided are useful as drugs for therapy and prevention of various types of diabetic complications.

  一种化合物由以下通式（A）表示 其中 Ra、Rb 和 Rc 中的两个是氧；X 是一种苄基、一种苯并噻唑基甲基或一种萘基甲基；R 是氢或低级烷基；n 是 1 至 3 的整数；Z 表示直接键或含有一个碳原子的桥基。 这些化合物是醛糖还原酶的选择性抑制剂。所提供的化合物可用作治疗和预防各种糖尿病并发症的药物。
• ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP0935601A2

  公开（公告）日：1999-08-18
• EP0935601A4
  申请人：——

  公开号：EP0935601A4

  公开（公告）日：2002-08-07